rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SVRA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week
      Nov 16Yahoo FinanceCAPRSVRA
      Savara investors brace for earnings ahead of key FDA ruling By Investing.com
      Nov 15Investing.comSVRA
      Savara: The Market May Be Overestimating Its FDA Risk (NASDAQ:SVRA)
      Nov 14Seeking AlphaSVRA
      Savara Announces New Employment Inducement Grant
      Nov 12Yahoo FinanceSVRA
      H.C. Wainwright initiates Savara stock coverage with buy rating
      Nov 12Investing.comSVRA
      Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
      Oct 21Yahoo FinanceSVRA
      Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?
      Oct 13Yahoo FinanceSVRA
      Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
      Oct 12Yahoo FinanceSVRA
      Savara Has Lost 30% Since December: JPMorgan Sees 146% Upside
      Oct 11Yahoo FinanceSVRAJPM
      JPMorgan Initiates Savara at Overweight With $12 Price Target
      Oct 7Yahoo FinanceSVRA
      Citizens reiterates Savara stock rating on Molbreevi launch outlook
      Oct 7Investing.comSVRA
      Savara presents molgramostim data at ERS Congress in September
      Aug 24Investing.comSVRA
      Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

      YARDLEY, Pa., August 24, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.

      Aug 24Yahoo FinanceSVRA

      This is the newest page. Registered accounts read further back.